Though many resources are often invested to create innovative and impactful technologies in laboratories, very few of these technologies make it to the market and become commercially available. Over the past 15 years, Micellae Delivery Systems Inc., led by founder and CEO Dr. Mehdi Nouraei, has strived to translate our scientific knowledge to produce the greatest economic, well-being, environmental, and social benefits.
In 2010, Dr. Nouraei was inspired by the work of Dr. Edgar Acosta at the U of T Department of Chemical Engineering, who had developed the first generations of “Lecithin Linker Microemulsions”, as a biocompatible, effective, and sustainable vehicle for enhancing the bioavailability of poorly soluble bioactive compounds. Over a 10-year period, Dr. Nouraei designed and optimized the next generation of those delivery systems.
Obtaining promising results on the performance of the next generation delivery systems, inspired him to create a company with the mission to provide the most advanced Drug Delivery System with food-grade excipients to significantly improve the solubility and bioavailability of hydrophobic bioactive compounds.
U of T entrepreneurship programs trained him to build the company and helped him raise funds and attract investors. As part of the 2017 cohort of the U of T Early-Stage Technology (UTEST) Program, Micellae built a partnership with Toronto Investment Acceleration Partners (TIAP), formerly knows as MaRS Innovation, which specializes in venture building of early-stage health science technologies.
In partnership with U of T and as per a “Technology Transfer Agreement”, Micellae was granted an exclusive license to use, optimize, and commercialize our IP-protected technology for use with cannabinoids as the first phase of commercialization. While O2W has the capability to enhance a wide variety of lipid-soluble compounds, currently, Micellae’s objective is to become the most valuable partner of high-quality pharmaceutical, medical, and recreational cannabis producers who aspire to produce the safest and highest performing products in a variety of dosage forms.
Micellae not only helps licensed producers through their cost-saving, performative, flexible, safe, sustainable, and evidence-backed technology, O2W, but also patients and consumers. With O2W, consumers can have access to high-quality, bioavailable cannabis at an affordable cost. Studies suggest that cannabinoids have a wide range of benefits ranging from treating rare forms of epilepsy to reducing anxiety. However, cannabinoids are considered to have low oral bioavailability, with only 4%-12% being absorbed in the gastrointestinal tract and reach the bloodstream. This means consumers only feel the effect of 4%-12% of the cannabinoids they ingest, which may not be enough to induce any therapeutic benefit. Given this, the need for an effective drug delivery system is vital to increasing the bioavailability of cannabinoids.
Moving forward, Micellae wants to align itself with partners that value innovation, safety, high quality, and evidence. If you want to create the most unique and innovative products on the market or bring your existing product to the next generation, connect with our experts.